- Home
- FFA vs CLLS Comparison
FFA vs CLLS Comparison
Compare FFA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | CLLS |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.4M | 374.2M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | FFA | CLLS |
|---|---|---|
| Price | $22.00 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 26.1K | ★ 42.6K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 6.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $15.84 | $1.10 |
| 52 Week High | $19.30 | $5.48 |
Technical Indicators
Market Signals| Indicator | FFA | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 44.43 |
| Support Level | $21.64 | $3.44 |
| Resistance Level | $22.31 | $3.98 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.49 | 36.30 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.